Sosei Heptares to introduce Restricted Share Units and Performance Share Units as new share-based incentive plans - Creating a globally consistent share-based incentive plan to encourage and reward corporate growth and better align with shareholders
Sosei Heptares starts new clinical development program - First subject dosed in Phase I study of HTL0030310, a selective SSTR5 (somatostatin 5) receptor agonist in development to treat endocrine disorders
Sosei Heptares starts new clinical development program – First subject dosed in Phase I study of HTL0014242, a selective mGlu5 negative allosteric modulator in development to treat psychiatric and neurological disorders
Sosei’s Strategic Minority Investment Company, MiNA Therapeutics, Announces Update From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference
Sosei subsidiary Heptares announces positive results from Phase 1b clinical trial with HTL9936, a first-in-class selective muscarinic M1 receptor agonist for improving cognition in dementia and schizophrenia
The UK BioIndustry Association (BIA) published a new report, Celebrating UK bioscience: unravelling the stories behind UK bioscience success, in which it highlights the background to and the importance of the Heptares StaR® technology.
Sosei Subsidiary Heptares launches ORBIT, a new collaborative R&D initiative designed to promote and broaden the application of its proprietary structure-based drug design expertise directed at G protein-coupled receptors (GPCRs)